Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | LDHB | P07195 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746236 | 1.00 | GAA (0.52) | GAASMN1; SMN2LDHALDHBKMT2A | |
| SCHEMBL20746570 | 0.90 | NPC1 (0.50) | SMN1; SMN2LDHALDHBKMT2AMEN1 | |
| SCHEMBL20746571 | 0.90 | NPC1 (0.50) | SMN1; SMN2LDHALDHBKMT2AMEN1 | |
| SCHEMBL20746448 | 0.89 | KMT2A (0.53) | SMN1; SMN2LDHALDHBKMT2AMEN1 | |
| SCHEMBL20746446 | 0.89 | KMT2A (0.53) | SMN1; SMN2LDHALDHBKMT2AMEN1 | |
| SCHEMBL20754505 | 0.89 | LDHA (0.51) | LDHALDHBKMT2AMAPTLMNA | |
| SCHEMBL22733793 | 0.89 | LDHA (0.51) | LDHALDHBKMT2AMAPTLMNA | |
| SCHEMBL20754516 | 0.88 | GAA (0.50) | GAASMN1; SMN2KMT2AMEN1MAPK1 | |
| SCHEMBL20746573 | 0.88 | EGFR (0.41) | GAASMN1; SMN2LDHALDHBKMT2A | |
| SCHEMBL20746572 | 0.88 | EGFR (0.41) | GAASMN1; SMN2LDHALDHBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385374-A1 | IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF TOLEDO (US) | 2020-12-10 | — | — | US | claimed |
| US-20200385374-A1 | IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF TOLEDO (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200385374-A1 | IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF TOLEDO (US) | 2020-12-10 | — | — | US | disclosed |
| WO-2019036607-A1 | IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF TOLEDO (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036607-A1 | IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF TOLEDO (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385374-A1 | IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME | HDAC1, HDAC8, HDAC2 | GAA 846/4885SMN1; SMN2 3892/4885LDHA 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.